BR9917605A - Composição substituta de plasma - Google Patents

Composição substituta de plasma

Info

Publication number
BR9917605A
BR9917605A BR9917605-0A BR9917605A BR9917605A BR 9917605 A BR9917605 A BR 9917605A BR 9917605 A BR9917605 A BR 9917605A BR 9917605 A BR9917605 A BR 9917605A
Authority
BR
Brazil
Prior art keywords
composition
plasma
relates
usable
substitute composition
Prior art date
Application number
BR9917605-0A
Other languages
English (en)
Inventor
Alexandr V Asafov
Tatiana D Asafov
Original Assignee
Alexandr V Asafov
Tatiana D Asafova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexandr V Asafov, Tatiana D Asafova filed Critical Alexandr V Asafov
Publication of BR9917605A publication Critical patent/BR9917605A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO SUBSTITUTA DE PLASMA". A invenção se refere à medicina, mais especificamente a invenção se refere a preparados farmacêuticos utilizáveis para o tratamento de lesões agudas e crónicas graves de um corpo humano, que são a causa de hipovolemia ou a alteração de propriedades funcionais de um sangue com sinais pronunciados de imunodeficiência. A invenção apresenta uma composição substituta de plasma que tem um efeito de imunomodulação. A invenção apresenta o uso de um agente de ingrediente biologicamente ativo específico que é um sal fisiologicamente aceitável de um derivado do DNA, preferivelmente um sal de sódio obtido a partir de matéria prima animal, tal como uma láctea de estujão ou de salmão. A composição proposta utilizável em uma terapia adjuvante estimula a hematopoiese e o mielopoiese sem nenhum efeito colateral ou complicações.
BR9917605-0A 1999-08-12 1999-08-12 Composição substituta de plasma BR9917605A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU1999/000289 WO2001012201A1 (fr) 1999-08-12 1999-08-12 Composition remplacant le plasma sanguin

Publications (1)

Publication Number Publication Date
BR9917605A true BR9917605A (pt) 2003-03-05

Family

ID=20130385

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917605-0A BR9917605A (pt) 1999-08-12 1999-08-12 Composição substituta de plasma

Country Status (9)

Country Link
EP (1) EP1210944A4 (pt)
JP (1) JP2003507334A (pt)
KR (1) KR20020031404A (pt)
CN (1) CN1379676A (pt)
AU (1) AU1299700A (pt)
BR (1) BR9917605A (pt)
CA (1) CA2380908A1 (pt)
MX (1) MXPA02001479A (pt)
WO (1) WO2001012201A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315184B1 (no) * 2001-09-26 2003-07-28 Firmenich & Cie Anvendelse av en sammensetning basert på fiskemelke for fremstilling av etpreparat som öker immunoglobulinproduksjonen
JP2004196701A (ja) * 2002-12-18 2004-07-15 Nissan Chem Ind Ltd 細胞死抑制剤
CN112316148A (zh) * 2019-08-01 2021-02-05 成都夸常奥普医疗科技有限公司 包含血浆的半流体的应用、包含该半流体和活性成分的药物组合物及其制备方法
CN113117172B (zh) * 2021-03-29 2024-06-11 佛山市博新生物科技有限公司 一种血液模拟介质及其制备方法和应用
KR102508983B1 (ko) * 2022-07-12 2023-03-10 이용광 철갑상어 수용성 오일을 함유하는 면역 증진용 조성물 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
JPS58502204A (ja) * 1981-12-31 1983-12-22 シンセテイック　ブラッド　コ−ポレ−ション 合成全血およびその製造方法
DE3501349A1 (de) * 1985-01-17 1986-07-17 Battelle-Institut E.V., 6000 Frankfurt Blutersatz
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
RU2063228C1 (ru) * 1993-02-04 1996-07-10 Юрий Петрович Вайнберг Способ лечения нарушений гемопоэза

Also Published As

Publication number Publication date
CA2380908A1 (en) 2001-02-22
WO2001012201A1 (fr) 2001-02-22
CN1379676A (zh) 2002-11-13
KR20020031404A (ko) 2002-05-01
EP1210944A4 (en) 2003-01-02
MXPA02001479A (es) 2003-07-21
AU1299700A (en) 2001-03-13
JP2003507334A (ja) 2003-02-25
WO2001012201A8 (fr) 2001-08-16
EP1210944A1 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
HK1061357A1 (en) Fibrate-statin combinations with reduced fed-fasted effects
TR200101633T2 (tr) Farmasötik bileşim
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
IL146133A0 (en) Preparations for the application of anti-inflammatory agents
BR9917605A (pt) Composição substituta de plasma
BRPI0413474A (pt) uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
CA2091134A1 (en) Therapeutic agent for threatened abortion
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
CA2403674A1 (en) The use of t3 for treating congestive heart failure
CA2336773A1 (en) Component b as angiogenic agent in combination with human growth factors
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
RU2002104662A (ru) Способ профилактики послеродового эндометрита у коров

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.